Faeth Therapeutics (FTH) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Faeth Therapeutics (FTH) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.29 of bullish evidence against -0.35 bearish.

Faeth Therapeutics last closed at $27.10, -4.41% on the session.

Against the IVW growth benchmark the position is -5.33% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

11 graded predictions for FTH so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Faeth Therapeutics in the 1st percentile on return on equity, where 100 is best.

Faeth Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $732.56M.

StockMap tracks Faeth Therapeutics as the 144th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Faeth Therapeutics ranks 228th of 344 in the group, against a group median of -0.21.